Case Studies

PATIENT-BASED MODEL TO CHALLENGE PRE-EXISTING EVALUATION OF A NOVEL THERAPEUTIC FOR A POPULATION WITH HIGH UNMET MEDICAL NEED

On March 12, 2015, In Case Studies,
A global biotechnology company had previously assessed the potential acquisition of a product with a novel mechanism of action, for use within a niche population with high unmet medical need. While the acquisition candidate was evaluated and found to fall short of the necessary threshold criteria in terms of forecast revenue potential, a similar asset was subsequently acquired by a top-ten multi-national pharmaceutical company. Our client now wishes to re-explore, in a robust and flexible way, the true potential of the agent for in-licensing. A patient-based model needs to be built, consisting of robust patient populations on which to evaluate…

CONCEPT TESTING OF AN INNOVATIVE IMAGING PLATFORM

On March 12, 2015, In Case Studies,
A market leading device manufacturer is in the process of developing the next generation of imaging technology. The designs are currently at a conceptual stage with the product profile being shaped by both customer insight and views from the development team. With an extended lead time required for both software and industrial design, many of the platform’s features must be agreed upon early in the development process in order to comply with the intended launch date. Qualitative research will be needed to confirm customer acceptance and to pin-point those attributes that will enhance product value. Guidance is needed in identifying…

ASIAN MARKET EXPANSION FOR NEW INFECTIOUS DISEASE TREATMENT

On March 12, 2015, In Case Studies, Tags
A global biopharmaceutical company is currently seeking approval to launch a new drug in several Asian countries for the treatment of a chronic, and endemic, infectious disease. Many of these markets have helped contain and reduce the spread of the disease though universal vaccination programmes implemented since the 1980s. However, this company is keen to understand the potential opportunity for their drug in these markets, and to gain insight into the key issues and potential barriers to entry in order to unlock full market revenue potential.

PAN-EUROPEAN STANDARDISATION OF FORECASTING PLATFORM

On February 9, 2015, In Case Studies,
A global biopharmaceutical company is seeking to standardise the forecasting approach used in their core European markets. There is currently no consistent format, structure or coverage across the different markets, with disparity between the level of expertise and resources available to generate forecasts. The company’s aim is to provide a standardised approach and forecasting tool to ensure robustness and consistency across their markets. The outcomes of this standardised approach will contribute to the company’s overall European commercial strategy.

QUANTIFYING THE MARKET POTENTIAL FOR A NEW PHARMACEUTICAL GRADE DIAGNOSTIC IMAGING AGENT

On December 4, 2014, In Case Studies, Tags
There is currently no industry standard database for Europe that identifies the location of PET/CT imaging sites and potential commercial cyclotron manufacturing sites. Unlike the US, the European market is fragmented with no true Pan-European manufacturing provider. As PET imaging technology transitions from a research-driven environment to a more commercially-driven one, much of this information is incomplete or not easily available for these markets.